• AAPL 181.71
  • TSLA 184.76
  • AMZN 188.7
  • MSFT 413.54
  • INTC 30.97
  • EURUSD 1.0763
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. IL /
  3. 0MGB.IL

Genmab A/S (0MGB IL) stock market data APIs

kr1956.75 -87.25(-4.3%) as of May 3, 2024

Genmab A/S Financial Data Overview

2044
1956.75
-
2066
1951
1824.5-2936
160 241 M
28.2747
65 313 K
16 366 M
0.6444
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '0MGB',
Type: 'Common Stock',
Name: 'Genmab A/S',
Exchange: 'IL',
CurrencyCode: 'DKK',
CurrencyName: 'Danish krone',
CurrencySymbol: 'kr',
CountryName: 'UK',
CountryISO: 'GB',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Genmab A/S Fundamental Data is available in our Financial Data APIs

  • Net Revenue 16 366 M
  • EBITDA 6 930 M
  • Earnings Per Share 70.77
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Genmab A/S Earnings via APIs

  • Latest Release 2024-05-02
  • EPS/Forecast NaN

Get Genmab A/S End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Genmab A/S latest news via APIs

Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript

Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript May 2, 2024 Genmab A/S reports earnings inline with expectations. Reported EPS is $0.16 EPS, expectations were $0.16. Genmab A/S isn’t one ...

Genmab Announces Financial Results for the First Quarter of 2024

Genmab A/S May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the s...
Do you have any questions?
support@eodhistoricaldata.com